Quality of life in purely ocular myasthenia in Japan

Shigeaki Suzuki, Hiroyuki Murai, Tomihiro Imai, Yuriko Nagane, Masayuki Masuda, Emiko Tsuda, Shingo Konno, Satoru Oji, Shunya Nakane, Masakatsu Motomura, Norihiro Suzuki, Kimiaki Utsugisawa

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Since there has been no conclusive evidence regarding the treatment of ocular myasthenia, treatment guidelines were recently issued by the European Federation of Neurological Societies/European Neurological Society (EFNS/ENS). However, the therapeutic outcomes concerning the quality-of-life (QOL) of patients with ocular myasthenia are not yet fully understood.Methods: We investigated the therapeutic outcomes of patients with purely ocular myasthenia in a multicenter cross-sectional survey in Japan. To evaluate the severity of ocular symptoms, we used the ocular-quantitative MG (QMG) score advocated by Myasthenia Gravis Foundation of America. We used the Japanese translated version of the MG-QOL15, a self-appraised scoring system.Results: Of 607 myasthenia gravis (MG) patients with an observation-duration of illness ≥ 2 years, the cases of 123 patients (20%) were limited to ocular muscles (purely ocular myasthenia). During the entire clinical course, 81 patients experienced both ptosis and diplopia, 36 had ptosis alone, and six had diplopia alone. Acetyl-cholinesterase inhibitors and prednisolone were used in 98 and 52 patients, respectively. Treatment improved ocular symptoms, with the mean reduction in ocular-QMG score of 2.3 ± 1.8 points. However, 47 patients (38%) failed to gain minimal manifestation or a better status. Patients with unfavorable outcomes also self-reported severe QOL impairment. Multivariate analyses showed that the pretreatment ocular-QMG score was associated with unfavorable outcomes, but not associated with the patient's QOL.Conclusion: A treatment strategy designed in accord with a patient's ocular presentation must be considered in order to improve ocular symptoms and the patient's QOL.

Original languageEnglish
Article number142
JournalBMC Neurology
Volume14
Issue number1
DOIs
Publication statusPublished - 2014 Jul 5

Fingerprint

Japan
Quality of Life
Myasthenia Gravis
Diplopia
Therapeutics
Cholinesterase Inhibitors
Prednisolone
Multivariate Analysis
Cross-Sectional Studies
Observation
Guidelines
Muscles

Keywords

  • Ocular myasthenia
  • Ocular-quantitative myasthenia gravis score
  • Quality-of-life
  • Therapeutic outcome

ASJC Scopus subject areas

  • Clinical Neurology
  • Medicine(all)

Cite this

Suzuki, S., Murai, H., Imai, T., Nagane, Y., Masuda, M., Tsuda, E., ... Utsugisawa, K. (2014). Quality of life in purely ocular myasthenia in Japan. BMC Neurology, 14(1), [142]. https://doi.org/10.1186/1471-2377-14-142

Quality of life in purely ocular myasthenia in Japan. / Suzuki, Shigeaki; Murai, Hiroyuki; Imai, Tomihiro; Nagane, Yuriko; Masuda, Masayuki; Tsuda, Emiko; Konno, Shingo; Oji, Satoru; Nakane, Shunya; Motomura, Masakatsu; Suzuki, Norihiro; Utsugisawa, Kimiaki.

In: BMC Neurology, Vol. 14, No. 1, 142, 05.07.2014.

Research output: Contribution to journalArticle

Suzuki, S, Murai, H, Imai, T, Nagane, Y, Masuda, M, Tsuda, E, Konno, S, Oji, S, Nakane, S, Motomura, M, Suzuki, N & Utsugisawa, K 2014, 'Quality of life in purely ocular myasthenia in Japan', BMC Neurology, vol. 14, no. 1, 142. https://doi.org/10.1186/1471-2377-14-142
Suzuki S, Murai H, Imai T, Nagane Y, Masuda M, Tsuda E et al. Quality of life in purely ocular myasthenia in Japan. BMC Neurology. 2014 Jul 5;14(1). 142. https://doi.org/10.1186/1471-2377-14-142
Suzuki, Shigeaki ; Murai, Hiroyuki ; Imai, Tomihiro ; Nagane, Yuriko ; Masuda, Masayuki ; Tsuda, Emiko ; Konno, Shingo ; Oji, Satoru ; Nakane, Shunya ; Motomura, Masakatsu ; Suzuki, Norihiro ; Utsugisawa, Kimiaki. / Quality of life in purely ocular myasthenia in Japan. In: BMC Neurology. 2014 ; Vol. 14, No. 1.
@article{aad18cfcbfc14039b3adbd50605bac25,
title = "Quality of life in purely ocular myasthenia in Japan",
abstract = "Background: Since there has been no conclusive evidence regarding the treatment of ocular myasthenia, treatment guidelines were recently issued by the European Federation of Neurological Societies/European Neurological Society (EFNS/ENS). However, the therapeutic outcomes concerning the quality-of-life (QOL) of patients with ocular myasthenia are not yet fully understood.Methods: We investigated the therapeutic outcomes of patients with purely ocular myasthenia in a multicenter cross-sectional survey in Japan. To evaluate the severity of ocular symptoms, we used the ocular-quantitative MG (QMG) score advocated by Myasthenia Gravis Foundation of America. We used the Japanese translated version of the MG-QOL15, a self-appraised scoring system.Results: Of 607 myasthenia gravis (MG) patients with an observation-duration of illness ≥ 2 years, the cases of 123 patients (20{\%}) were limited to ocular muscles (purely ocular myasthenia). During the entire clinical course, 81 patients experienced both ptosis and diplopia, 36 had ptosis alone, and six had diplopia alone. Acetyl-cholinesterase inhibitors and prednisolone were used in 98 and 52 patients, respectively. Treatment improved ocular symptoms, with the mean reduction in ocular-QMG score of 2.3 ± 1.8 points. However, 47 patients (38{\%}) failed to gain minimal manifestation or a better status. Patients with unfavorable outcomes also self-reported severe QOL impairment. Multivariate analyses showed that the pretreatment ocular-QMG score was associated with unfavorable outcomes, but not associated with the patient's QOL.Conclusion: A treatment strategy designed in accord with a patient's ocular presentation must be considered in order to improve ocular symptoms and the patient's QOL.",
keywords = "Ocular myasthenia, Ocular-quantitative myasthenia gravis score, Quality-of-life, Therapeutic outcome",
author = "Shigeaki Suzuki and Hiroyuki Murai and Tomihiro Imai and Yuriko Nagane and Masayuki Masuda and Emiko Tsuda and Shingo Konno and Satoru Oji and Shunya Nakane and Masakatsu Motomura and Norihiro Suzuki and Kimiaki Utsugisawa",
year = "2014",
month = "7",
day = "5",
doi = "10.1186/1471-2377-14-142",
language = "English",
volume = "14",
journal = "BMC Neurology",
issn = "1471-2377",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Quality of life in purely ocular myasthenia in Japan

AU - Suzuki, Shigeaki

AU - Murai, Hiroyuki

AU - Imai, Tomihiro

AU - Nagane, Yuriko

AU - Masuda, Masayuki

AU - Tsuda, Emiko

AU - Konno, Shingo

AU - Oji, Satoru

AU - Nakane, Shunya

AU - Motomura, Masakatsu

AU - Suzuki, Norihiro

AU - Utsugisawa, Kimiaki

PY - 2014/7/5

Y1 - 2014/7/5

N2 - Background: Since there has been no conclusive evidence regarding the treatment of ocular myasthenia, treatment guidelines were recently issued by the European Federation of Neurological Societies/European Neurological Society (EFNS/ENS). However, the therapeutic outcomes concerning the quality-of-life (QOL) of patients with ocular myasthenia are not yet fully understood.Methods: We investigated the therapeutic outcomes of patients with purely ocular myasthenia in a multicenter cross-sectional survey in Japan. To evaluate the severity of ocular symptoms, we used the ocular-quantitative MG (QMG) score advocated by Myasthenia Gravis Foundation of America. We used the Japanese translated version of the MG-QOL15, a self-appraised scoring system.Results: Of 607 myasthenia gravis (MG) patients with an observation-duration of illness ≥ 2 years, the cases of 123 patients (20%) were limited to ocular muscles (purely ocular myasthenia). During the entire clinical course, 81 patients experienced both ptosis and diplopia, 36 had ptosis alone, and six had diplopia alone. Acetyl-cholinesterase inhibitors and prednisolone were used in 98 and 52 patients, respectively. Treatment improved ocular symptoms, with the mean reduction in ocular-QMG score of 2.3 ± 1.8 points. However, 47 patients (38%) failed to gain minimal manifestation or a better status. Patients with unfavorable outcomes also self-reported severe QOL impairment. Multivariate analyses showed that the pretreatment ocular-QMG score was associated with unfavorable outcomes, but not associated with the patient's QOL.Conclusion: A treatment strategy designed in accord with a patient's ocular presentation must be considered in order to improve ocular symptoms and the patient's QOL.

AB - Background: Since there has been no conclusive evidence regarding the treatment of ocular myasthenia, treatment guidelines were recently issued by the European Federation of Neurological Societies/European Neurological Society (EFNS/ENS). However, the therapeutic outcomes concerning the quality-of-life (QOL) of patients with ocular myasthenia are not yet fully understood.Methods: We investigated the therapeutic outcomes of patients with purely ocular myasthenia in a multicenter cross-sectional survey in Japan. To evaluate the severity of ocular symptoms, we used the ocular-quantitative MG (QMG) score advocated by Myasthenia Gravis Foundation of America. We used the Japanese translated version of the MG-QOL15, a self-appraised scoring system.Results: Of 607 myasthenia gravis (MG) patients with an observation-duration of illness ≥ 2 years, the cases of 123 patients (20%) were limited to ocular muscles (purely ocular myasthenia). During the entire clinical course, 81 patients experienced both ptosis and diplopia, 36 had ptosis alone, and six had diplopia alone. Acetyl-cholinesterase inhibitors and prednisolone were used in 98 and 52 patients, respectively. Treatment improved ocular symptoms, with the mean reduction in ocular-QMG score of 2.3 ± 1.8 points. However, 47 patients (38%) failed to gain minimal manifestation or a better status. Patients with unfavorable outcomes also self-reported severe QOL impairment. Multivariate analyses showed that the pretreatment ocular-QMG score was associated with unfavorable outcomes, but not associated with the patient's QOL.Conclusion: A treatment strategy designed in accord with a patient's ocular presentation must be considered in order to improve ocular symptoms and the patient's QOL.

KW - Ocular myasthenia

KW - Ocular-quantitative myasthenia gravis score

KW - Quality-of-life

KW - Therapeutic outcome

UR - http://www.scopus.com/inward/record.url?scp=84904426456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904426456&partnerID=8YFLogxK

U2 - 10.1186/1471-2377-14-142

DO - 10.1186/1471-2377-14-142

M3 - Article

C2 - 24996227

AN - SCOPUS:84904426456

VL - 14

JO - BMC Neurology

JF - BMC Neurology

SN - 1471-2377

IS - 1

M1 - 142

ER -